

**S3 Table.** Excluded 106 studies after full text assessment [1-106]

- 
1. Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. *Crit Rev Oncol Hematol.* 2002;43:57-62.
  2. Shapiro M, Rashid NU, Huang Q, Galper SL, Boosalis VA, Whang EE, et al. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States. *JAMA Surg.* 2015;150:274-7.
  3. Feng D, Leong M, Li T, Chen L, Li T. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. *World J Surg Oncol.* 2015;13:11.
  4. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. *Br J Surg.* 2009;96:1015-22.
  5. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. *Lancet Oncol.* 2013;14:317-26.
  6. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2008;72:678-86.
  7. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. *Cancer J.* 2007;13:247-56.
  8. Goji T, Kimura T, Miyamoto H, Takehara M, Kagemoto K, Okada Y, et al. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. *Cancer Chemother Pharmacol.* 2015;76:615-20.
  9. Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. *Oncotarget.* 2015;6:24560-70.
  10. Hartlapp I, Muller J, Kenn W, Steger U, Isbert C, Scheurlen M, et al. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. *Onkologie.* 2013;36:123-5.
  11. Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. *Pancreas.* 2009;38:e69-74.
  12. Cassinotto C, Mouries A, Lafourcade JP, Terrebonne E, Belleanne G, Blanc JF, et al. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. *Radiology.* 2014;273:108-16.
  13. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. *Am J Surg.* 1995;169:71-7.
  14. Hurt CN, Mukherjee S, Bridgewater J, Falk S, Crosby T, McDonald A, et al. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2015;93:810-8.
  15. Kapoor R, Khosla D, Gupta R, Bahl A, Shukla AK, Sharma SC. Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: a feasibility study at tertiary care centre. *Indian J Cancer.* 2014;51:176-9.
  16. Kemp KR, Liehr JG, Giovanella B. Combined radiation and 9-nitrocamptothecin (rubitecan) in the treatment of locally advanced pancreatic cancer. *Ann N Y Acad Sci.*
-

---

2000;922:320-3.

17. Raju PI, Maruyama Y, MacDonald J, DeSimone P. Treatment of unresectable pancreatic carcinoma using irradiation with concurrent intravenous 5-FU infusion therapy. *Cancer Invest.* 1988;6:263-6.
  18. Safran H, Cioffi W, Iannitti D, Mega A, Akerman P. Paclitaxel and concurrent radiation for locally advanced pancreatic carcinoma. *Front Biosci.* 1998;3:E204-6.
  19. Weese JL, Nussbaum ML, Paul AR, Engstrom PF, Solin LJ, Kowalyszyn MJ, et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. *Int J Pancreatol.* 1990;7:177-85.
  20. Adhoute X, Smith D, Vendrely V, Rault A, Sa Cunha A, Legoux JL, et al. Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. *Gastroenterol Clin Biol.* 2006;30:224-30.
  21. Azria D, Seblain-El Guerche C, Girard N, Hennequin C, Huguet F. Systematic review of the value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma. *Cancer Radiother.* 2009;13:216-28.
  22. Azria D, Seblain-El-Guerche C, Girard N, Hennequin C, Huguet F. The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review. *Bull Cancer.* 2008;95:1116-30.
  23. Baba H, Kurata M, Tsuruta K, Okamoto A, Karasawa K. [Low-dose gemcitabine concurrent with radiation therapy for locally advanced pancreatic carcinoma]. *Gan To Kagaku Ryoho.* 2006;33:1863-5.
  24. Baba H, Suzuki Y, Ema T, Kawakami M, Nakanishi C, Hashimoto T, et al. Gemcitabine concurrent with radiation for locally advanced pancreatic cancer. *Gan To Kagaku Ryoho.* 2005;32:1730-2.
  25. Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCO/SFRO phase III trial. *Cancer Radiother.* 2011;15:182-91.
  26. Brunner T. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. *Strahlenther Onkol.* 2012;188:366-7.
  27. Brunner T, Sauer R. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. *Strahlenther Onkol.* 2009;185:839-40.
  28. Delpero JR, Turrini O. Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection. *Cancer Radiother.* 2006;10:462-70.
  29. Jensen HA, Nielsen HO, Jensen JD, Fristrup CW, Nielsen M, Pfeiffer P. Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy. *Ugeskr Laeger.* 2008;170:639-41.
  30. Niki T, Soejima T, Yoshikawa T, Yamamoto Y, Fujii O, Ohta Y, et al. 5-FU based chemoradiotherapy for unresectable locally advanced pancreatic cancer. *Gan To Kagaku Ryoho.* 2009;36:63-9.
  31. Yamazaki H, Nishiyama K, Koizumi M. Concurrent chemoradiotherapy using full-dose gemcitabine for patients with unresectable pancreatic cancer. *Nihon Igaku Hoshasen Gakkai Zasshi.* 2004;64:216-9.
  32. Allendorf JD, Laueran M, Bill A, DiGiorgi M, Goetz N, Vakiani E, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. *J Gastrointest Surg.* 2008;12:91-100.
  33. Andren-Sandberg A, Holmberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. *Scand J Gastroenterol.*
-

---

1983;18:609-12.

34. Aristu J, Canon R, Pardo F, Martinez-Monge R, Martin-Algarra S, Manuel Ordonez J, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. *Am J Clin Oncol*. 2003;26:30-6.
  35. Baize N, Abu Shalaa A, Berthier F, Demarquay JF, Bernard JL, Rahili A, et al. Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. *Gastroenterol Clin Biol*. 2005;29:1006-9.
  36. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, Marimastat Pancreatic Cancer Study G. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. *J Clin Oncol*. 2001;19:3447-55.
  37. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. *Br J Cancer*. 2002;87:161-7.
  38. Bukowski RM, Abderhalden RT, Hewlett JS, Weick JK, Groppe CW, Jr. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. *Cancer Clin Trials*. 1980;3:321-4.
  39. Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingston RB. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. *Cancer*. 1982;50:197-200.
  40. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, et al. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. *J Chemother*. 2004;16:589-94.
  41. Chen L, Haraf D, Brachman D, Vokes E, Schilsky R. Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer. *Oncol Rep*. 1997;4:877-81.
  42. Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. *Int J Radiat Oncol Biol Phys*. 1994;30:161-7.
  43. Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalglish AG, Knight MJ. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. *Br J Cancer*. 1996;73:1260-4.
  44. Lygidakis NJ, Dedemati G, Spenzaris N, Theodoropoulou M. Unresectable pancreatic cancer: is a multi-modality approach a promising therapeutical alternative? *Hepatogastroenterology*. 1997;44:1222-8.
  45. Michael A, Hill M, Maraveyas A, Dalglish A, Lofts F. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer: report of a pilot phase II study. *Clin Oncol (R Coll Radiol)*. 2007;19:150-3.
  46. Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, et al. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study. *Invest New Drugs*. 2011;29:144-53.
  47. Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. *J Clin Oncol*. 2008;26:942-7.
  48. Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for
-

---

Pancreatic Cancer. *Ann Oncol.* 2001;12:101-3.

49. Wilkowski R, Thoma M, Duhmke E, Rau HG, Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. *Int J Radiat Oncol Biol Phys.* 2004;58:768-72.
  50. Bajetta E, Di Bartolomeo M, Artale S, Stani S, Ricci SB, Cassata A, et al. Oral doxifluridine (5-dFUR) and radiation therapy for unresectable locally advanced pancreatic cancer: a phase II study of Italian Trials In Medical Oncology (ITMO) Group. *Ann Oncol.* 1998;9:51.
  51. Belluomini MA, Vasile E, De Lio N, Costa F, Cappelli C, Campani D, et al. Resection of locally advanced pancreatic cancer after neoadjuvant chemotherapy with modified FOLFIRINOX: a prospective phase II study. *J Pancreas* 2013;14:530.
  52. Berardi R, Sobrero A, Labianca R, Bidoli P, Siena S, Ferrari D, et al. Sorafenib does not improve the results of chemotherapy in advanced pancreatic cancer: a GISCAD randomised phase II trial. *Ann Oncol.* 2010;21:225.
  53. Bjerregaard JK, Schonemann KR, Jensen HA, Mortensen MB, Hansen TP, Pfeiffer P. Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy: results from 64 patients treated from 2001-2005. *J Clin Oncol.* 2008;26(15 Suppl):4624.
  54. Blazer MA, Wu CS, Goldberg RM, Phillips GS, Schmidt CR, Muscarella P, et al. Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). *J Clin Oncol.* 2014;32(3 Suppl):275.
  55. Brunner TB, Grabenbauer GG, Kasti S, Hohenberger W, Sauer R. Preoperative simultaneous chemoradiation in locally advanced ductal pancreatic carcinoma. *Radiology.* 1998;209:436.
  56. Cardenes HR, Powell M, Loehrer PJ, Wagner LI, Cella DF, Brell J, et al. E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with locally advanced, unresectable, pancreatic cancer (LAPC): quality-of-life (QOL) analysis. *J Clin Oncol.* 2009;27(15S):4627.
  57. Chang KJ, Fisher W, Kenady D, Klapman J, Posner M, Reid T, et al. Multicenter randomized controlled phase III clinical trial using TNFerade (TNF) with chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC): Interim analysis (IA) of overall survival (OS). *J Clin Oncol.* 2009;27(15S):4605.
  58. Chaudhary UB, Gudena V, Milling DL, O'Brien P, Montero AJ, Brashears J, et al. Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer. *J Clin Oncol.* 2008;26(15 Suppl):15506.
  59. Chlebowski R, Gota C, Glass A, Weiner J, Bateman JR. Combination chemotherapy with cyclophosphamide plus 5-fluorouracil for treatment of unresectable pancreatic adenocarcinoma. *Clin Res.* 1978;26:A432.
  60. Chung HW, Park JY, Kim SA, Shin Y, Park SW, Chung JB, et al. Comparison of concurrent chemoradiation between paclitaxel/furtulon and gemcitabine/furtulon for the locally advanced pancreatic adenocarcinoma. *Gastroenterology.* 2002;122:A599.
  61. Cooray P, Dean AP. Neoadjuvant therapy with nanoparticle albumin-bound (nab)-paclitaxel to enhance the resectability of locally advanced pancreatic cancer (LAPC). *J Clin Oncol.* 2012;30:e14644.
  62. Crane C, Varadhachary G, Javle M, Safran H, Krishnan S, Fleming J et al. Phase II trial of cetuximab gem and oxali, followed by XRT with concurrent cape, and cetuximab, for locally advanced pancreatic adenocarcinoma (lapc). *HPB.* 2010;12:112-3.
-

- 
63. De Lio N, Vasile E, Belluomini MA, Costa F, Cappelli C, Campani D, et al. Resection of locally advanced pancreatic cancer after neoadjuvant chemotherapy with modified FOLFIRINOX: a prospective phase II study. *Pancreatology*. 2013;13:S88-9.
  64. Dholakia AS, Chang DT, Goodman KA, Raman SP, Hacker-Prietz A, Griffith ME, et al. A phase 2 multicenter study to evaluate gemcitabine and fractionated stereotactic body radiation therapy for locally advanced pancreatic adenocarcinoma. *Int J Radiat Oncol Biol Phys*. 2013;87:S28.
  65. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. *J Natl Cancer Inst*. 1988;80:751-5.
  66. Esnaola NF, Garrett-Mayer E, O'Brien P, Camp ER, Thomas M, Cole DJ, et al. R0 resection after induction gemcitabine/oxaliplatin/cetuximab +/- capecitabine-based chemoradiation for locally advanced pancreatic cancer. *Ann Surg Oncol*. 2010;17:S64-5.
  67. Golcher H, Witzigmann H, Marti L, Lange J, Bechstein W, Bruns C, et al. Preoperative chemoradiation for resectable adenocarcinoma of the pancreas (ISRCTN 78805636): results of a randomized trial. *J Cancer Res Clin Oncol*. 2012;138:22.
  68. Hosein PJ, Kawamura C, Macintyre J, Loaiza-Bonilla A, Merchan JR, Levi JU, et al. Pilot study of neoadjuvant FOLFIRINOX in unresectable locally advanced (LA) pancreatic carcinoma (PC). *J Clin Oncol*. 2011;29(4 Suppl):324.
  69. Ioka T, Katayama K, Ashida R, Takada R. Phase I/II study of concurrent chemoradiotherapy with gemcitabine and S-1 for unresectable locally advanced pancreatic adenocarcinoma. *HPB*. 2014;16:253-4.
  70. Shinci H, Maemura K, Mataka Y, Kurahara H, Natsugoe S, Takao S. Phase II study of S-1 with concurrent radiotherapy for locally advanced unresectable pancreatic cancer. *Pancreatology*. 2010;10:89-90.
  71. Vasile E, De Lio N, Belluomini MA, Costa F, Cappelli C, Campani D, et al. Resection of locally advanced pancreatic cancer after neoadjuvant chemotherapy with modified folfirinox: a prospective phase II study. *HPB*. 2014;16:292-3.
  72. Amano R, Kimura K, Nakata B, Yamazoe S, Motomura H, Yamamoto A, et al. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer. *Surgery*. 2015;158:191-200.
  73. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. *J Gastrointest Surg*. 2003;7:766-72.
  74. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. *Cancer*. 2012;118:3026-35.
  75. Atasoy BM, Dane F, Ucuncu Kefeli A, Caglar H, Cingi A, Turhal NS, et al. Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer. *Turk J Gastroenterol*. 2011;22:60-4.
  76. Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, et al. Induction chemotherapy followed by concurrent full-dose gemcitabine and intensity-modulated radiation therapy for borderline resectable and locally advanced pancreatic adenocarcinoma. *Am J Clin Oncol*. 2016;39:1-7.
  77. Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. *Am J Surg*. 2012;203:132-9.
  78. Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P. Prognostic
-

- 
- factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. *Int J Radiat Oncol Biol Phys.* 2012;83:909-15.
79. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. *J Surg Oncol.* 2013;108:236-41.
80. Botwinick IC, Schrope BA, Chabot JA. Distal pancreatectomy with en bloc celiac axis resection after neoadjuvant therapy for locally advanced pancreatic adenocarcinoma. *Pancreas.* 2010;39:1111-3.
81. Brunner TB, Tinkl D, Grabenbauer GG, Meyer T, Brueckl WM, Sauer R. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients. *Strahlenther Onkol.* 2006;182:210-5.
82. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? *Int J Radiat Oncol Biol Phys.* 2002;52:1293-302.
83. Denost Q, Laurent C, Adam JP, Capdepon M, Vendrely V, Collet D, et al. Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. *HPB (Oxford).* 2013;15:716-23.
84. Epelboym I, DiNorcia J, Winner M, Lee MK, Lee JA, Schrope BA, et al. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. *World J Surg.* 2014;38:1184-95.
85. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. *Oncologist.* 2013;18:543-8.
86. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. *Ann Surg.* 2015;261:12-7.
87. Fisher BJ, Perera FE, Kocha W, Tomiak A, Taylor M, Vincent M, et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 1999;45:291-5.
88. Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, et al. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. *Clin Oncol (R Coll Radiol).* 2010;22:564-9.
89. Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas: a single centre experience advocating a new treatment strategy. *Eur J Surg Oncol.* 2008;34:756-64.
90. Huang PI, Chao Y, Li CP, Lee RC, Chi KH, Shiau CY, et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2009;73:159-65.
91. Huang WK, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, et al. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. *Anticancer Res.* 2014;34:6755-61.
92. Igarashi H, Ito T, Kawabe K, Hisano T, Arita Y, Kaku T, et al. Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. *World J Gastroenterol.* 2008;14:5311-5.
93. Kang H, Chang JS, Oh TG, Chung MJ, Park JY, Park SW, et al. Full-dose
-

---

gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.

Chemotherapy. 2014;60:191-9.

94. Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. *Pancreatology*. 2015;15:667-73.

95. Kim HS, Yi SY, Jun HJ, Lee J, Park SH, Lee JK, et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. *Anticancer Drugs*. 2010;21:107-12.

96. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. *Cancer*. 2007;110:47-55.

97. Mawdsley S, Hall M, Glynne-Jones R. Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. *Clin Oncol (R Coll Radiol)*. 2002;14:308-12.

98. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. *Am J Clin Oncol*. 2001;24:155-9.

99. Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. *Acta Oncol*. 2015;54:979-85.

100. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2007;68:801-8.

101. Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. *J Surg Oncol*. 2015;111:1028-34.

102. Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, et al. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. *Ann Surg Oncol*. 2015;22 Suppl 3:S1212-20.

103. Opendro SS, Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, et al. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? *J Hepatobiliary Pancreat Sci*. 2014;21:695-702.

104. Park JK, Ryu JK, Lee JK, Yoon WJ, Lee SH, Kim YT, et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. *Pancreas*. 2006;33:397-402.

105. Tada M, Arizumi T, Nakai Y, Sasaki T, Kogure H, Togawa O, et al. Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy. *Chemotherapy*. 2008;54:302-8.

106. Wang BH, Cao WM, Yu J, Wang XL. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. *Asian Pac J Cancer Prev*. 2012;13:2129-32.

---